Actively Recruiting
Cardio-Oncology Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
Led by University of Michigan Rogel Cancer Center · Updated on 2026-05-04
10
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
U
University of Michigan Rogel Cancer Center
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating a Cardio-Oncology Prehabilitation program designed for patients at high risk of cardiovascular events who are preparing to undergo Hematopoietic Stem Cell Transplantation (HSCT). The study aims to assess the feasibility and early effectiveness of this program in improving cardiorespiratory fitness and reducing acute cardiovascular complications in these patients. The program involves a multimodal approach including an individualized exercise plan based on a detailed cardiovascular assessment and medical management of cardiovascular risk factors. This intervention is delivered over an 8-week period at home, starting with an initial cardiovascular evaluation and concluding with a follow-up assessment before HSCT. Participants will be engaged in personalized exercise sessions monitored for adherence and effectiveness. Researchers will measure outcomes such as recruitment and retention rates, adherence to the program, changes in cardiorespiratory fitness markers like anaerobic threshold and VO2peak, symptom scores, quality of life, and biomarkers. The study duration for each participant is 8 weeks post enrollment, with safety and feasibility outcomes carefully tracked throughout.
CONDITIONS
Brief Title
Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult 18 years or older
- Referred for Hematopoietic Stem Cell Transplant evaluation
- Have at least one cardiovascular risk factor such as hypertension, high cholesterol, atrial fibrillation, obesity, heart failure, coronary artery disease, or diabetes
- Able to walk without assistance
- Able to understand and willing to sign informed consent
- Able to use Polar Flow heart rate app
You will not qualify if you...
- Severe anemia (hemoglobin less than 7 gm/dl)
- Untreated high-risk coronary artery disease (left main, triple vessel disease)
- Severe aortic stenosis
- Recent bone fracture
- Major balance problems
- Severe pain with basic movement
- Unable to walk without assistance or to exercise
- NYHA class IV heart failure
- Adults unable to give consent, pregnant women, and prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants undergo an 8-week at-home, personalized exercise intervention following an initial cardiovascular evaluation as part of standard care.
Initial cardiovascular assessment and follow-up assessment after 8 weeks
Trial Site Locations
Total: 1 location
1
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
Research Team
C
Cancer AnswerLine
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here